Cytokinetics (CYTK) Share-based Compensation (2010 - 2026)
Cytokinetics (CYTK) posted quarterly Share-based Compensation of $13.1 million for Q1 2026, up 274.18% year-over-year from $3.5 million in Q1 2025, and down 88.2% quarter-over-quarter from $111.0 million in Q4 2025.
Cytokinetics (CYTK) Share-based Compensation (2010 - 2026) Analysis & Trends
Cytokinetics (CYTK) has reported Share-based Compensation for 17 consecutive years, with $13.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Share-based Compensation rose 274.18% year-over-year to $13.1 million; the TTM figure through Mar 2026 stood at $13.1 million (down 83.57% YoY), while the FY2025 annual figure was $112.3 million, up 14.76% from the prior year.
- Share-based Compensation retreated to $13.1 million in Q1 2026 per CYTK's latest filing, from $111.0 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $111.0 million in Q4 2025 and bottomed at -$42.1 million in Q4 2023.
- Historically, Share-based Compensation has averaged $17.4 million across 5 years, with a median of $15.2 million in 2023.
- On a YoY basis, Share-based Compensation climbed as much as 2061.31% in 2023 and fell as far as 676.97% in 2023.
- Cytokinetics' Share-based Compensation stood at $7.3 million in 2022, then sank by 676.97% to -$42.1 million in 2023, then surged by 162.41% to $26.2 million in 2024, then surged by 323.01% to $111.0 million in 2025, then sank by 88.2% to $13.1 million in 2026.
- Business Quant data shows CYTK's Share-based Compensation at $13.1 million in Q1 2026, $111.0 million in Q4 2025, and $1.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Cytokinetics | 10.31 Bn | 9.14 Bn | 25.89 Mn | 35.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 35.71 Mn |
| Jun 30, 2026 | 35.71 Mn |
| Mar 31, 2026 | 13.10 Mn |
| Mar 31, 2026 | 13.10 Mn |
| Dec 31, 2025 | 111.04 Mn |
| Dec 31, 2025 | 111.04 Mn |
| Sep 30, 2025 | 1.30 Mn |
| Sep 30, 2025 | 1.30 Mn |
| Jun 30, 2025 | 27.54 Mn |
| Jun 30, 2025 | 27.54 Mn |
| Mar 31, 2025 | 3.50 Mn |
| Mar 31, 2025 | 3.50 Mn |
| Dec 31, 2024 | 26.25 Mn |
| Dec 31, 2024 | 26.25 Mn |
| Sep 30, 2024 | 25.36 Mn |
| Sep 30, 2024 | 25.36 Mn |
| Jun 30, 2024 | 24.62 Mn |
| Jun 30, 2024 | 24.62 Mn |
| Mar 31, 2024 | 18.45 Mn |
| Mar 31, 2024 | 18.45 Mn |